PURPOSE: 18F-Fluorodeoxyglucose (FDG) imaging, provided by current positron emission tomography (PET) systems dedicated to small animals,might provide a precise functional assessment of the left ventricle (LV) in rats, although conventional metabolic conditioning by hyperinsulinaemic glucose clamping is not well adapted to this setting. This study was aimed at assessing cardiac FDG PET in rats premedicated with acipimox, a potent nicotinic acid derivative yielding comparable image quality to clamping in man. METHODS: Metabolic conditioning was compared in Wistar rats between a conventional oral glucose loading (1.5 mg/kg) and acipimox, which was given at high but well tolerated doses subcutaneously (25 mg/kg) or orally (50 mg/kg). Myocardial to blood (M/B) activity ratio and myocardial signal to noise (S/N) ratio were analysed on gated FDG PET images. RESULTS: The S/N ratio of the gated cardiac images evolved in parallel with the M/B activity ratio and these two ratios were independently enhanced by glucose loading and acipimox. However, these enhancements were: (1) dramatic for acipimox, especially for the high oral dose of 50 mg/kg (from 2.85 +/- 0.57 to 10.73 +/- 0.54 for the M/B ratio of rats with or without glucose loading; p<0.0001) and (2) much more limited for glucose loading (from 6.61 +/- 0.49 to 7.89 +/- 0.41 for the M/B ratio of rats with or without acipimox administration; p=0.049). With the high oral dose of acipimox, the gated cardiac FDG PET images had very high S/N ratios, at least equivalent to those currently documented in man. CONCLUSION: Metabolic conditioning by oral doses of acipimox is highly efficient for experimental studies planned with cardiac FDG PET in rats.
PURPOSE:18F-Fluorodeoxyglucose (FDG) imaging, provided by current positron emission tomography (PET) systems dedicated to small animals,might provide a precise functional assessment of the left ventricle (LV) in rats, although conventional metabolic conditioning by hyperinsulinaemic glucose clamping is not well adapted to this setting. This study was aimed at assessing cardiac FDG PET in rats premedicated with acipimox, a potent nicotinic acid derivative yielding comparable image quality to clamping in man. METHODS: Metabolic conditioning was compared in Wistar rats between a conventional oral glucose loading (1.5 mg/kg) and acipimox, which was given at high but well tolerated doses subcutaneously (25 mg/kg) or orally (50 mg/kg). Myocardial to blood (M/B) activity ratio and myocardial signal to noise (S/N) ratio were analysed on gated FDG PET images. RESULTS: The S/N ratio of the gated cardiac images evolved in parallel with the M/B activity ratio and these two ratios were independently enhanced by glucose loading and acipimox. However, these enhancements were: (1) dramatic for acipimox, especially for the high oral dose of 50 mg/kg (from 2.85 +/- 0.57 to 10.73 +/- 0.54 for the M/B ratio of rats with or without glucose loading; p<0.0001) and (2) much more limited for glucose loading (from 6.61 +/- 0.49 to 7.89 +/- 0.41 for the M/B ratio of rats with or without acipimox administration; p=0.049). With the high oral dose of acipimox, the gated cardiac FDG PET images had very high S/N ratios, at least equivalent to those currently documented in man. CONCLUSION: Metabolic conditioning by oral doses of acipimox is highly efficient for experimental studies planned with cardiac FDG PET in rats.
Authors: Takashi Kudo; Kazuki Fukuchi; Alexander J Annala; Arion F Chatziioannou; Vivekanand Allada; Magnus Dahlbom; Yuan-Chuan Tai; Masayuki Inubushi; Sung-Cheng Huang; Simon R Cherry; Michael E Phelps; Heinrich R Schelbert Journal: Circulation Date: 2002-07-02 Impact factor: 29.690
Authors: Fatiha Maskali; Philippe R Franken; Sylvain Poussier; Nguyen Tran; Chris Vanhove; Henri Boutley; Hervé Le Gall; Gilles Karcher; Faïez Zannad; Patrick Lacolley; Pierre Y Marie Journal: J Nucl Med Date: 2006-02 Impact factor: 10.057
Authors: Wolfgang M Schaefer; Claudia S A Lipke; Bernd Nowak; Hans Juergen Kaiser; Arno Buecker; Gabriele A Krombach; Udalrich Buell; Harald P Kühl Journal: Eur J Nucl Med Mol Imaging Date: 2003-02-15 Impact factor: 9.236
Authors: Takahiro Higuchi; Stephan G Nekolla; Antanas Jankaukas; Axel W Weber; Marc C Huisman; Sybille Reder; Sibylle I Ziegler; Markus Schwaiger; Frank M Bengel Journal: J Nucl Med Date: 2007-02 Impact factor: 10.057
Authors: Daniel Thomas; Harshali Bal; Jeffrey Arkles; James Horowitz; Luis Araujo; Paul D Acton; Victor A Ferrari Journal: Magn Reson Med Date: 2008-02 Impact factor: 4.668
Authors: Ester Carballo-Jane; Lynn S Gerckens; Silvi Luell; Allison S Parlapiano; Michael Wolff; Steven L Colletti; James R Tata; Andrew K P Taggart; M Gerard Waters; Jeremy G Richman; Margaret E McCann; Michael J Forrest Journal: J Pharmacol Toxicol Methods Date: 2007-06-23 Impact factor: 1.950
Authors: Catherine Chapon; Johanna S Jackson; Eric O Aboagye; Amy H Herlihy; William A Jones; Kishore K Bhakoo Journal: Mol Imaging Biol Date: 2008-09-05 Impact factor: 3.488
Authors: Fatiha Maskali; Sylvain Poussier; Huguette Louis; Henri Boutley; Mickael Lhuillier; Simon N Thornton; Gilles Karcher; Patrick Lacolley; Pierre Y Marie Journal: Int J Cardiovasc Imaging Date: 2014-01-03 Impact factor: 2.357
Authors: Yvan Devaux; Melanie Bousquenaud; Sophie Rodius; Pierre-Yves Marie; Fatiha Maskali; Lu Zhang; Francisco Azuaje; Daniel R Wagner Journal: BMC Med Genomics Date: 2011-12-05 Impact factor: 3.063
Authors: Mona S Hansen; Asger Andersen; Lars P Tolbod; Nils H Hansson; Roni Nielsen; Anton Vonk-Noordegraaf; Jens Erik Nielsen-Kudsk Journal: Pulm Circ Date: 2017-11-03 Impact factor: 3.017